Quantinno Capital Management’s Candel Therapeutics CADL Stock Holding History

Quantinno Capital Management’s Portfolio CADL Stock Details CADL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$143K	Buy	+13,670	New	+$151K	﹤0.01%	3549

Other funds holding CADL

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Kennedy Capital Management St Louis, Missouri $5.31B AUM 40.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

Sands Capital Ventures Arlington, Virginia $695M AUM 31.12% 1-Year Est. Return

Quantinno Capital Management's CADL Position: Q3 2026 in Review

Quantinno Capital Management opened a new position in Candel Therapeutics (CADL) in Q3 2026: 13,670 shares worth $143K. The stake represents ﹤0.01% of the portfolio and ranks #3549 among its holdings.

106 funds tracked by Wall St. Rank hold CADL as of Q3 2026.

Quantinno Capital Management held 13,670 shares of Candel Therapeutics worth $143K as of Q3 2026.
Candel Therapeutics was a new Quantinno Capital Management position in Q3 2026.
Candel Therapeutics made up ﹤0.01% of Quantinno Capital Management's portfolio in Q3 2026, its #3549 holding.
106 funds tracked by Wall St. Rank held Candel Therapeutics as of Q3 2026.

Based on Quantinno Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.